drugset / Trial / NCT03164473
Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.
Phase 3
Completed
98 enrolled
Assistance Publique - Hôpitaux de Paris
French Vasculitis Study Group · collabURC-CIC Paris Descartes Necker Cochin · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to investigate, after achievement of remission, the efficacy of rituximab compared with azathioprine maintenance therapy on duration of remission, in patients with relapsing or newly-diagnosed Eosinophilic granulomatosis with polyangiitis EPGA receiving standard of care therapy including glucocorticoid therapy reduction/withdrawal.
Timeline
- Start
- 2018-03-07
- Primary completion
- 2024-09-23
- Completion
- 2024-09-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azathioprine | Small molecule | 2 mg/kg | Oral |
| Subject | Rituximab | Monoclonal antibody | 500 mg | Intravenous |